Stockholders’ Equity (Details) - USD ($) |
1 Months Ended | 12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jan. 19, 2021 |
Dec. 08, 2020 |
Dec. 03, 2020 |
Nov. 12, 2020 |
Nov. 03, 2020 |
Aug. 14, 2020 |
Jun. 03, 2020 |
May 06, 2020 |
Aug. 05, 2021 |
Jan. 29, 2021 |
Dec. 31, 2020 |
Dec. 16, 2020 |
Sep. 27, 2019 |
Dec. 31, 2021 |
Aug. 08, 2021 |
Dec. 31, 2020 |
Dec. 31, 2018 |
Nov. 05, 2021 |
Sep. 09, 2020 |
Dec. 31, 2019 |
|
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Preferred stock, authorized | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||||||||||
| Preferred stock, par value (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
| Preferred stock, shares Issued | ||||||||||||||||||||
| Certificate of designation series A preferred stock | 5,000,000 | |||||||||||||||||||
| Percentage purchase price | 25.00% | |||||||||||||||||||
| Purchase price (in Dollars) | $ 6 | |||||||||||||||||||
| Effective interest rate | 25.00% | |||||||||||||||||||
| Effective conversion price (in Dollars) | $ 6 | |||||||||||||||||||
| Stockholder debt term | 1 year | |||||||||||||||||||
| Preferred stock, shares outstanding | ||||||||||||||||||||
| Conversion of aggregate of shares | 979,361 | |||||||||||||||||||
| Aggregate of shares | 195,881 | |||||||||||||||||||
| Percentage of premium | 25.00% | |||||||||||||||||||
| Additional aggregate of shares issued | 15,093 | |||||||||||||||||||
| Reverse stock split, description | On November 3, 2020, the Board of Directors of the Company approved a one-for-three reverse stock split of the Company’s authorized and outstanding common stock, effective November 13, 2020 (the “Reverse Stock Split”). On November 12, 2020, Company filed a Certificate of Change to the Company’s Articles of Incorporation with the Secretary of State of the State of Nevada to effect the Reverse Stock Split. The Reverse Stock Split became effective at 5:31 p.m. | All common stock, stock options, restricted stock units, warrants and related per share amounts for all periods presented have been retroactively adjusted to give effect to the Reverse Stock Split. | ||||||||||||||||||
| Common stock, authorized | 116,666,667 | 116,666,667 | 116,666,667 | |||||||||||||||||
| Public offering, description | the Company entered into an underwriting agreement (the “Underwriting Agreement”) with the Underwriters, relating to the Company’s public offering (the ”2020 Public Offering”) of 5,000,000 shares (the “2020 Firm Shares”) of the Company’s Common Stock, par value $0.0001 per share. Pursuant to the 2020 Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 750,000 shares of Common Stock (the “2020 Option Shares,” and together with the 2020 Firm Shares, the “2020 Shares”) to cover over-allotments. | the Company entered into an underwriting agreement (the “2021 Underwriting Agreement”) with Oppenheimer & Co. Inc., acting as the representative for the underwriters identified therein (the “Underwriters”), relating to the Company’s public offering (the “2021 Public Offering”) of 6,400,000 shares (the “2021 Firm Shares”) of the Company’s Common Stock. Pursuant to the 2021 Underwriting Agreement, the Company also granted the Underwriters a 30-day option to purchase up to an additional 960,000 shares of Common Stock (the “2021 Option Shares,” and together with the 2021 Firm Shares, the “2021 Shares”) to cover over-allotments.The Underwriters agreed to purchase the 2021 Firm Shares from the Company with the option to purchase the 2021 Option Shares at a price of $6.51 per share. The 2021 Shares were offered, issued, and sold pursuant to the Form S-3 and accompanying prospectus filed with the SEC under the Securities Act. On June 11, 2021, pursuant to the 2021 Public Offering, the Company issued 7,360,000 shares of Common Stock (2021 Firm Shares and 2021 Option Shares) at a public price of $7.00 for net proceeds to the Company of $47,523,569 after deducting the underwriting discount and offering fees and expenses payable by the Company. | ||||||||||||||||||
| Number of warrants to purchase | 289,253 | |||||||||||||||||||
| Additional net proceeds (in Dollars) | $ 47,523,569 | |||||||||||||||||||
| Warrants outstanding to purchase an aggregate | 3,305,854 | |||||||||||||||||||
| Options term | 5 years 2 months 26 days | |||||||||||||||||||
| Stock options exercise price (in Dollars per share) | $ 7.39 | $ 6.79 | $ 7.89 | $ 7.39 | $ 9.75 | |||||||||||||||
| Weighted average exercise price (in Dollars per share) | $ 8.53 | |||||||||||||||||||
| Warrants to purchase an aggregate of common stock (in Dollars per share) | $ 1,565,656 | |||||||||||||||||||
| Fully vested warrant term | 5 years | |||||||||||||||||||
| Stock options to purchase common stock, description | On August 5, 2021, the Company issued 211,038 Stock Options to employees of American Robotics in connection with the merger. Of these Stock Options 50,543 were issued as fully vested with no further service obligations and were included in the purchase consideration. The remaining 151,495 vest over a four-year period and are contingent on ongoing employment. They are included in compensation expense. | As of December 31, 2021, we had Stock Options outstanding to purchase an aggregate of 856,198 shares of Common Stock with a weighted-average contractual remaining life of approximately 8.76 years, and exercise prices ranging from $1.37 to $12.92 per share, resulting in a weighted average exercise price of $6.72 per share. | As of December 31, 2020, we had Stock Options outstanding to purchase an aggregate of 568,006 shares of Common Stock with a weighted-average contractual remaining life of approximately 9.45 years, and exercise prices ranging from $6.39 to $12.72 per share, resulting in a weighted average exercise price of $7.39 per share. | |||||||||||||||||
| Compensation expense related to non-vested options (in Dollars) | $ 864,679 | |||||||||||||||||||
| Weighted-average period | 3 years 10 months 24 days | |||||||||||||||||||
| Restricted stock units description | the Company entered into employment agreements and awarded 1,375,000 restricted stock units pursuant to the 2018 Plan to key members of American Robotics’ management. Each restricted stock unit represents a contingent right to receive one share of common stock of the Company. The restricted stock units vest in three successive equal annual installments with the first vesting date commencing on the first anniversary of the award date and are contingent on continuing employment. The compensation expense recognized in 2021 in respect of these restricted stock units was $1,452,385, and as of December 31, 2021 the unrecognized compensation expense was $9,245,115.On January 25, 2021, the Compensation Committee approved the following grants: (a) for Messrs. Cohen, Reisfield and Silverman (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (b) for Mr. Seidl and Ms. Sood (i) 5,000 restricted stock units pursuant to the 2018 Plan, and (ii) 10,000 restricted stock units pursuant to the 2018 Plan. | |||||||||||||||||||
| Unrecognized compensation expense (in Dollars) | $ 127,200 | |||||||||||||||||||
| Restricted stock purchase | 1,000,000 | |||||||||||||||||||
| Shares options issued non-vested, description | Non-vested RSUs as of December 31, 2020 totalled 625,0000 shares. | |||||||||||||||||||
| recognized compensation expense (in Dollars) | $ 3,150,000 | $ 1,050,000 | $ 3,150,000 | |||||||||||||||||
| Convertible Preferred Stock [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Preferred stock, shares outstanding | 2,350,390 | |||||||||||||||||||
| Securities Purchase Agreement [Member] | Placement Agent [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Reimbursement of transaction expenses (in Dollars) | $ 6 | |||||||||||||||||||
| Number of warrants to purchase | 26,762,000 | |||||||||||||||||||
| Equity Incentive Plan [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Common stock reserved for issuance | 3,333,334 | |||||||||||||||||||
| Reverse Stock Split [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Agreement, description | Eastern Time, on November 13, 2020. No fractional shares will be issued as a result of the Reverse Stock Split. Any fractional shares that would result from the Reverse Stock Split will be rounded up to the nearest whole share. Following the Reverse Stock Split, the Company has 116,666,667 shares of Common Stock authorized. | |||||||||||||||||||
| Equity Incentive Plan [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Common stock reserved for issuance | 6,000,000 | |||||||||||||||||||
| Restricted Stock Units (RSUs) [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Weighted-average contractual remaining life | 1 year 3 months | |||||||||||||||||||
| Compensation committee grants | 6,362 | |||||||||||||||||||
| Restricted stock purchase | 126,160 | |||||||||||||||||||
| Stock compensation expense (in Dollars) | $ 3,150,000 | |||||||||||||||||||
| Weighted average grant-date fair value of exercise price (in Dollars per share) | $ 8.4 | |||||||||||||||||||
| Vesting period | 2 years | 2 years | ||||||||||||||||||
| recognized compensation expense (in Dollars) | $ 5,250,000 | $ 5,250,000 | ||||||||||||||||||
| Description of restricted stock units | Effective January 19, 2021, (i) Mr. Bushey received 500,000 RSUs (375,000 RSUs vested as of December 31, 2020 and 125,000 RSUs on which the Compensation Committee accelerated vesting), which RSUs will be issued on June 3, 2022 pursuant to Mr. Bushey’s deferral election, and (ii) 500,000 RSUs were cancelled. | |||||||||||||||||||
| Weighted average grant-date fair value (in Dollars per share) | $ 0.64 | |||||||||||||||||||
| Restricted Stock Units (RSUs) [Member] | Consultant [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Stock compensation expense (in Dollars) | $ 0 | $ 30,357 | ||||||||||||||||||
| Securities Purchase Agreement [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Agreement, description | the Company entered into securities purchase agreements (the “2020 Purchase Agreements”) with certain purchasers (the “2020 Investors”), which provided for the sale of an aggregate of $4,435,000 ($4,483,749 after payment of offering expenses) and the exchange for debt of $265,779 of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred”) at a purchase price of $2.00 per share (the “Purchase Price”) (the “Offering”). On August 14, 2020 and August 27, 2020, pursuant to the 2020 Purchase Agreements, the Company issued an aggregate of 2,350,390 shares of Series A Preferred to the 2020 Investors (collectively the “2020 Closing”). In connection with the 2020 Closing, Eric Brock, the Company’s Chief Executive Officer purchased 157,500 shares of Series A Preferred. | |||||||||||||||||||
| Over-Allotment Option [Member] | Securities Purchase Agreement [Member] | Investor [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Description of transaction | a shelf Registration Statement on Form S-3 for up to $150,000,000 with the SEC (the “Form S-3”) for shares of its Common Stock; shares of its preferred stock, which the Company may issue in one or more series or classes; debt securities, which the company may issue in one or more series; warrants to purchase its Common Stock, preferred stock or debt securities; and units. The Form S-3 was declared effective by the SEC on February 5, 2021. | |||||||||||||||||||
| Public Offering [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Number of shares issued | 5,000,000 | |||||||||||||||||||
| Convertible Notes Payable [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Warrants outstanding to purchase an aggregate | 46,893 | |||||||||||||||||||
| Convertible Notes Payable [Member] | Other Financing Agreements [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Debt principal and interest outstanding amount (in Dollars) | $ 120,000 | |||||||||||||||||||
| Minimum [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Stock options exercise price (in Dollars per share) | $ 0.03 | |||||||||||||||||||
| Maximum [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Stock options exercise price (in Dollars per share) | $ 9.75 | |||||||||||||||||||
| Preferred Stock [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Preferred stock, authorized | 116,666,667 | |||||||||||||||||||
| Preferred stock, par value (in Dollars per share) | $ 0.0001 | |||||||||||||||||||
| Preferred stock, shares Issued | 40,990,604 | |||||||||||||||||||
| Preferred stock description | On December 31, 2021, the Company had 10,000,000 shares of preferred stock, par value $0.0001, authorized, of which 5,000,000 shares are designated as Series A Convertible Preferred Stock (“Series A Preferred”) and 5,000,000 shares are non-designated (“blank check”) shares. As of December 31, 2021 and December 31, 2020, the Company had no preferred stock outstanding. | |||||||||||||||||||
| Additional net proceeds (in Dollars) | ||||||||||||||||||||
| Common Stock [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Common stock, authorized | 116,666,667 | |||||||||||||||||||
| Number of shares issued | 750,000 | 7,360,000 | ||||||||||||||||||
| Additional net proceeds (in Dollars) | $ 4,200,000 | $ 736 | ||||||||||||||||||
| Warrant [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Number of warrants to purchase | 231,543 | |||||||||||||||||||
| Warrants exercise price (in Dollars per share) | $ 7.5 | $ 9.75 | ||||||||||||||||||
| Description of warrant rights | On May 6, 2020, the Company’s Board granted (i) an aggregate of 47,917 Warrants with an exercise price of $7.50 per share and a grant date fair value of $1.00 per share, and (ii) an aggregate of 9,793 Warrants with an exercise price of $6.39 per share and a grant date fair value of $1.71 per share. | |||||||||||||||||||
| Warrant fair value (in Dollars per share) | $ 1,361,149 | |||||||||||||||||||
| Stock options to purchase | 231,543 | |||||||||||||||||||
| Warrants to purchase shares | 139,605 | |||||||||||||||||||
| Warrant [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Number of warrants to purchase | 1,879,803 | 1,879,803 | ||||||||||||||||||
| Weighted-average contractual remaining life | 2 years 2 months 12 days | |||||||||||||||||||
| Warrants exercise price (in Dollars per share) | $ 9.16 | $ 9.16 | ||||||||||||||||||
| Warrant [Member] | Minimum [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Warrant fair value (in Dollars per share) | $ 1.4 | |||||||||||||||||||
| Warrant [Member] | Minimum [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Warrants exercise price (in Dollars per share) | 0.03 | 0.03 | ||||||||||||||||||
| Warrant [Member] | Maximum [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Warrant fair value (in Dollars per share) | $ 2.37 | |||||||||||||||||||
| Warrant [Member] | Maximum [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||||||||||||
| Warrants exercise price (in Dollars per share) | $ 9.75 | $ 9.75 | ||||||||||||||||||